Literature DB >> 36219353

Constructed the ceRNA network and predicted a FEZF1-AS1/miR-92b-3p/ZIC5 axis in colon cancer.

Xiaoping Yang1,2, Pingfan Wu3, Zirui Wang2, Xiaolu Su4, Zhiping Wu5, Xueni Ma1,2, Fanqi Wu1,6, Dekui Zhang7,8.   

Abstract

The purpose of this study was to identify the role of FEZF1-AS1 in colon cancer and predicted the underlying mechanism. We extracted sequencing data of colon cancer patients from The Cancer Genome Atlas database, identified the differential expression of long noncoding RNA, microRNA, and messenger RNA, constructed a competitive endogenous RNA network, and then analyzed prognosis. Then, we used the enrichment analysis databases for functional analysis. Finally, we studied the FEZF1-AS1/miR-92b-3p/ZIC5 axis. We detected the expression of FEZF1-AS1, miR-92b-3p, and ZIC5 via quantitative reverse transcription-PCR, transfected colon cancer cell RKO with lentivirus and conducted FEZF1-AS1 knockdown, and performed cancer-related functional assays. It indicated that many RNA in the competitive endogenous RNA network, such as ZIC5, were predicted to be related to overall survival of colon cancer patients, and enrichment analysis showed cancer-related signaling pathways, such as PI3K/AKT signaling pathway. The expression of FEZF1-AS1 and ZIC5 was significantly higher and that of miR-92b-3p was lower in the colon cancer than in the normal colon tissues. FEZF1-AS1 promoted the migration, proliferation, as well as invasion of RKO. According to the prediction, FEZF1-AS1 and ZIC5 might competitively bind to miR-92b-3p, leading to the weakening of the inhibitory impact of miR-92b-3p on ZIC5 and increasing expression of ZIC5, thus further activating the PI3K/AKT signaling pathway, which led to the occurrence and development of colon cancer. The study suggested that FEZF1-AS1 might be an effective diagnosis biomarker for colon cancer.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarker; Colon cancer; Competing endogenous RNA network; FEZF1-AS1; Survival; lncRNA

Year:  2022        PMID: 36219353     DOI: 10.1007/s11010-022-04578-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.842


  69 in total

Review 1.  Biomarkers in cancer staging, prognosis and treatment selection.

Authors:  Joseph A Ludwig; John N Weinstein
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

Review 2.  Noncoding RNAs in the development, diagnosis, and prognosis of colorectal cancer.

Authors:  Mingjiao Weng; Di Wu; Chao Yang; Haisheng Peng; Guangyu Wang; Tianzhen Wang; Xiaobo Li
Journal:  Transl Res       Date:  2016-10-14       Impact factor: 7.012

3.  Colorectal cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ann Goding Sauer; Stacey A Fedewa; Lynn F Butterly; Joseph C Anderson; Andrea Cercek; Robert A Smith; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-03-05       Impact factor: 508.702

4.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

5.  Nano-herb medicine and PDT induced synergistic immunotherapy for colon cancer treatment.

Authors:  Xiaoli Wu; Han Yang; Xingmeng Chen; Junxiao Gao; Yue Duan; Daohe Wei; Jinchao Zhang; Kun Ge; Xing-Jie Liang; Yuanyu Huang; Sizhou Feng; Rongli Zhang; Xi Chen; Jin Chang
Journal:  Biomaterials       Date:  2021-01-05       Impact factor: 12.479

6.  Long noncoding RNA ZFAS1 promoting small nucleolar RNA-mediated 2'-O-methylation via NOP58 recruitment in colorectal cancer.

Authors:  Huizhe Wu; Wenyan Qin; Senxu Lu; Xiufang Wang; Jing Zhang; Tong Sun; Xiaoyun Hu; Yalun Li; Qiuchen Chen; Yuanhe Wang; Haishan Zhao; Haiyan Piao; Rui Zhang; Minjie Wei
Journal:  Mol Cancer       Date:  2020-05-22       Impact factor: 27.401

7.  Distinct metabolic programs established in the thymus control effector functions of γδ T cell subsets in tumor microenvironments.

Authors:  Noella Lopes; Claire McIntyre; Stefania Martin; Mathilde Raverdeau; Bruno Silva-Santos; Daniel J Pennington; Lydia Lynch; Nital Sumaria; Ayano C Kohlgruber; Gina J Fiala; Leandro Z Agudelo; Lydia Dyck; Harry Kane; Aaron Douglas; Stephen Cunningham; Hannah Prendeville; Roisin Loftus; Colleen Carmody; Philippe Pierre; Manolis Kellis; Michael Brenner; Rafael J Argüello
Journal:  Nat Immunol       Date:  2021-01-18       Impact factor: 25.606

8.  Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer.

Authors:  Wenlong Du; Xiaoping Yang; Shenfu He; Jia Wang; Yuanxian Guo; Bangguo Kou; Yongjie Jiang; Pan Bian; Bingtai Li; Lanning Yin
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

9.  Prevalence and risk factors for colorectal polyps in a Chinese population: a retrospective study.

Authors:  Jiaqi Pan; Li Cen; Lei Xu; Min Miao; Youming Li; Chaohui Yu; Zhe Shen
Journal:  Sci Rep       Date:  2020-04-24       Impact factor: 4.379

10.  PEGylated Nanographene Oxide in Combination with Near-Infrared Laser Irradiation as a Smart Nanocarrier in Colon Cancer Targeted Therapy.

Authors:  Milena Georgieva; Zlatina Gospodinova; Milena Keremidarska-Markova; Trayana Kamenska; Galina Gencheva; Natalia Krasteva
Journal:  Pharmaceutics       Date:  2021-03-22       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.